Industry Trends

Our 20th annual listing highlights brand surges, new ranking battles, and M&A-sparked upswings, but in the shadow of COVID-19, a peek behind the numbers also tells another story.

Pharma is boosting outreach and its image, as the industry faces a defining period in its quest to sway the tide of public perception.

Considerations for biopharma to transform itself beyond the COVID-19 crisis, by Arda Ural.

Every major pharma company undertakes some form of diversity and inclusion work. However, that doesn’t mean it’s reaching the decision-makers, writes Stephen Frost.

Melonie Warfel discusses the challenges organizations are facing when it comes to revenue management and looks at the key areas to optimize.

In 2020 and beyond, succeeding in the new ecosystem means focusing on delivering value backed by data, tailored engagements with a diverse range of distinctly defined stakeholders, and monitoring the rapidly evolving healthcare space for new trends that will impact success.

The research community is moving quickly to launch clinical trials of potential countermeasures, while regulatory authorities aim to support product development through regulatory flexibility.

Pharm Exec’s annual forecast of the key issues facing biopharma leaders in the year ahead taps experts from several areas to uncover the seven new-decade trends to watch.

Hari Pujar, chief technology officer of Spark Therapeutics, discusses the unique manufacturing and scale-up challenges involved with cell and gene therapy production.

Pharrm Exec's 2020 Pipeline Report

As the microbiome "moves into the mainstream," Pharm Exec looks at how industry activity in the space is heating up.

Healthy companies with coherent integration strategies will benefit from applying six lessons to ensure successful integration, writes Mark Bouch.

As payers increasingly stifle new drug launches, investors in biopharmaceutical companies pursue better sources of insights.

Pharm Exec’s latest analysis of financial performance reveals that it’s those drugmakers maximizing the difference between the value and the cost of their capital investments that are delivering the most bang for the buck to shareholders.

As well as official European projections of sharply slowing industry growth and geopolitical concerns, pharma executives face additional hazards as they plot their medium-term strategies, writes Reflector.

Clive Glover and Mark Szczypka discuss the complexities of scaling up the manufacturing of gene therapies and gene-modified cell therapies to industrial levels.

A 2019 study reveals further marginal decline in the pharma industry's reputation. Sven Klingemann suggests some "recovery solutions".

Our 19th annual listing reveals some interesting maneuvering of ranks, as companies focus on diversification, big-brand expansions, and positioning a new wave of products to compete in an advancing but complex future treatment market.

While culture may "eat" strategy, shared understanding creates both culture and strategy, write Steve Figman and Sean Robertson.

The opioid crisis dominated the news in this year’s annual audit of press coverage of the pharmaceutical industry. Stephen J. Porth and George P. Sillup report.

The World Health Assembly's new resolution on transparency in the market for health-related products is weaker than the original draft but still contains measures that could have a substantial impact on market access around the world, writes Neil Grubert.

Findings support the belief that today’s pharma finance teams should be engaged across all functional areas, including regulatory, supply chain, manufacturing, and commercial. What does that mean for current and future CFOs in the industry?

The outlook for pharma M&A continues to be strong, writes Michael Jewell.

Stefan Spazek outlines the steps for biopharma startups in tapping non-dilutive financing options.